These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8172802)

  • 61. Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.
    Jones SE; Mennel RG; Peters GN; Westrick MA; Brooks BD; Knox SM; McGuffey P
    Invest New Drugs; 1988 Sep; 6(3):195-8. PubMed ID: 2847991
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
    Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 65. What were the received dose intensities in the three arms?
    Hryniuk WM
    J Clin Oncol; 1991 Jul; 9(7):1321-2. PubMed ID: 2045873
    [No Abstract]   [Full Text] [Related]  

  • 66. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Blumenschein GR; Hug V; Hortobagyi GN
    Cancer; 1987 Jun; 59(12):1992-9. PubMed ID: 3567861
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
    Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
    Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer.
    Mackay HJ; Bissett D; Twelves C; Vasey PA
    Clin Oncol (R Coll Radiol); 1999; 11(3):174-8. PubMed ID: 10465471
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results.
    Zaniboni A; Simoncini E; Marpicati P; Montini E; Ferrari V; Ferragni A; Boari L; Marini G
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1151-5. PubMed ID: 2788577
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
    Sørensen B; Bastholt L; Mirza MR; Gjedde SB; Jakobsen P; Mouridsen HT; Rose C
    Cancer Chemother Pharmacol; 1994; 34(5):439-43. PubMed ID: 8070013
    [TBL] [Abstract][Full Text] [Related]  

  • 74. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.
    van der Wall E; Richel DJ; Kusumanto YH; Rutgers EJ; Schornagel JH; Schaake-Koning CC; Peterse JL; Rodenhuis S
    Ann Oncol; 1993 Nov; 4(9):791-2. PubMed ID: 8280661
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Equalization of spread of breast cancer chemotherapy regimen at general hospitals--with EC and FEC regimens].
    Kitada N; Nakayama T; Morita S; Sasaoka H; Yamasaki H; Anami S; Tatsuta M; Furukawa H; Morimoto S; Miyabe T; Hasegawa K; Tabuse K; Takara K; Yokoyama T; Watari M
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):267-71. PubMed ID: 18281763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
    Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
    Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
    J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
    Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
    Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.